I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the groundbreaking news about AstraZeneca’s Imfinzi and Imjudo
What if a single drug could redefine survival chances for thousands facing lung cancer surgery in Europe? Imagine a patient, newly diagnosed with non-small cell lung cancer (NSCLC), grappling with the uncertainty of whether their tumor can be removed and if they’ll face recurrence. For many, this
What happens when a disease as merciless as amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), strikes a tiny fraction of patients with a genetic twist that makes it even deadlier? For the roughly 2% of ALS sufferers with mutations in the SOD1 gene, life has often felt
What if a single monthly infusion could halt the heartbreaking decline of memory and independence for millions of Europeans with early Alzheimer’s disease, bringing hope to families across the continent? This question, once a distant dream, now edges closer to reality with donanemab, a pioneering
In the complex world of oncology, multiple myeloma (MM) stands as a formidable challenge, affecting thousands across Europe with its intricate disease mechanisms and diverse patient needs. As the second most common blood cancer after non-Hodgkin lymphoma, MM impacts around 46,000 new individuals
The European Medicines Agency (EMA) has recommended the approval of Moderna's LP.8.1-adapted COVID-19 vaccine to address the challenges posed by the SARS-CoV-2 variant LP.8.1. Following the guidance of EMA's Emergency Task Force, the formulation of Spikevax has been tailored to combat the current
